Navigation Links
Dr. Chris Huber Joins Asymchem Laboratories Inc. as Director of Chemical Development
Date:5/20/2009

MORRISVILLE, N.C., May 20 /PRNewswire/ --Asymchem Laboratories, Inc., a leading research-based contract manufacturer of API's, intermediates and Drug Products to the pharmaceutical industry, with sites in the U.S. and China, is pleased to announce the recent addition of Dr. Chris Huber as Director of Chemical Development.

Dr. Huber brings to the table over 15 years experience in the pharmaceutical industry (early and late stage), developing process technology for API manufacturing of small molecules. Prior to Asymchem, Dr. Huber directed early phase projects for API manufacturing at Achaogen Inc. and Arena Pharmaceuticals. Much of his career was spent in Pfizer and legacy companies in process chemistry, with focus on optimization, characterization and validation of Phase 3 processes in preparation for commercial manufacturing of API.

As Director of Chemical Development, Dr. Huber will help expand and strengthen Asymchem's pilot scale-up, tech transfers and production efforts into commercial manufacturing. He will report directly to Dr. Jim Gage, VP of Chemical Development.

"I am very pleased to have Dr. Huber on board to help expand and strengthen Asymchem's already well-established large scale manufacturing services," states Dr Hao Hong, CEO of Asymchem. "With his broad experience in the pharmaceutical industry and proven track record of API manufacturing, I am confident that our commercial capabilities will be further strengthened and solidified."

Dr. Huber received his B.S. and M.S. at the Universitat Regensburg , Germany under the supervision of Professors Dr. Henri Brunner, Dr. Jurgen Sauer and Dr. Josef Barthel. He earned his Ph.D. in Organic Chemistry and Catalysis from the Universitat Regensburg, Germany with Professor Dr. Henri Brunner. He did his post doc at Purdue University, Indiana under Professor Thomas Bein on the development of supported organometallic catalysts with application in organic synthesis.

Asymchem Laboratories is a leading research-based contract manufacturer specialized in the development and compliant manufacturing (Contract Research and Manufacturing Services) of API's and Drug Products serving the pharmaceutical industry. With a 14yr track record, Asymchem is committed to the highest level of quality and excellence in the integrated CMC services arena. For further information, please visit the Asymchem website at www.asymchem.com.


'/>"/>
SOURCE Asymchem Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Fina Technologies Names Spotfire Founder Christopher Ahlberg to Board of Directors
2. Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise
3. VITAS Innovative Hospice Care(R) Names Christopher Rieder Senior Vice President and Chief Information Officer
4. Christopher and Dana Reeve Foundation Response to FDA Clearance of Gerons Clinical Trial
5. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
6. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
7. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
8. Christine Poon Will Keynote MichBio Expo
9. Quintiles Appoints Christopher Cabell to Chief Medical and Scientific Officer
10. Adnavance Technologies Inc. Appoints Christian P. Valcke, Ph.D., to Its Scientific Advisory Board
11. Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -- Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
(Date:3/28/2017)... March 28, 2017  Viking Therapeutics, Inc. ("Viking") (NASDAQ: ... of novel therapies for metabolic and endocrine disorders, today ... , Ph.D., will deliver a corporate presentation at H.C. ... Conference, being held April 3, 2017 at the St. ... for this presentation are as follows: ...
(Date:3/28/2017)... ... March 28, 2017 , ... Currently symptomatic therapies for ... recent study published in STEM CELLS suggests that human neural stem cell (hNSC) ... to produce more neural cells. , Strategies involving transplantation of these cells ...
(Date:3/28/2017)... Triangle Park, NC (PRWEB) , ... March 28, ... ... development company engaged in the development of a new orally administered treatment for ... Advisory Board. , CEO John Didsbury states, “As we seek to uniquely treat ...
Breaking Biology Technology:
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):